Feb 7 (Reuters) - H Lundbeck A/S HLUNb.CO :
* LUNDBECK ANNOUNCES FINANCIAL GUIDANCE FOR 2023 AND
MID-TERM
FINANCIAL TARGETS THAT BUILD ON VERY STRONG 2022 PERFORMANCE
* FY2023 GUIDANCE REVENUE: DKK 19.4 - 20.0 BILLION
* FINANCIAL GUIDANCE FOR 2023 REFLECTS EXPECTED INVESTMENTS
NEEDED
FOR THESE IMPORTANT LAUNCHES DRIVING SIGNIFICANT FUTURE GROWTH
* EXPECTS 2023 EBITDA AT DKK 4.8 - 5.2 BILLION
* WE EXPECT THAT IN 2023 AND 2024 THERE WILL BE TARGETED
INVESTMENTS BEHIND POTENTIAL BLOCKBUSTER OPPORTUNITY FOR
BREXPIPRAZOLE FOR TREATMENT OF AGITATION ASSOCIATED WITH
ALZHEIMER'S DEMENTIA
* MID-TERM TARGETS: WE EXPECT REVENUE TO SHOW A MID-SINGLE
DIGIT
COMPOUND ANNUAL GROWTH RATE (CAGR) OVER MID-TERM, (3-4 YEARS)
* MID-TERM TARGETS: WE TARGET AN EBITDA-MARGIN OF 30-32% FOR
CURRENT BUSINESS, EXCLUDING ANY BUSINESS DEVELOPMENT ACTIVITIES
BY END OF MID-TERM PERIOD
* IN 2022, REVENUE REACHED DKK 18.2 BILLION, HIGHEST EVER IN
LUNDBECK'S HISTORY, WITH A SOLID GROWTH OF 7% IN LOCAL
CURRENCIES (12% REPORTED)
* PRELIMINARY 2022 EBITDA REACHED DKK 4,663 MILLION,
REFLECTING
VERY STRONG GROWTH OF 25%
Source text for Eikon: ID:nWkr5ZzcDY
Further company coverage: HLUNb.CO
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))